These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 35484930)

  • 1. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients.
    Oh JH; Lee JM; Lee HJ; Hwang J; Lee CH; Cho YK; Park HS; Yoon HJ; Chung JW; Kim H; Nam CW; Han S; Hur SH; Youn JC; Kim IC
    ESC Heart Fail; 2022 Aug; 9(4):2435-2444. PubMed ID: 35484930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
    Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
    Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction.
    Mohebi R; Liu Y; Felker GM; Prescott MF; Ward JH; Piña IL; Butler J; Solomon SD; Januzzi JL
    J Card Fail; 2022 Dec; 28(12):1673-1682. PubMed ID: 36122820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment.
    Lee YH; Chiou WR; Hsu CY; Lin PL; Liang HW; Chung FP; Liao CT; Lin WY; Chang HY
    Eur Heart J Cardiovasc Pharmacother; 2022 Feb; 8(2):118-129. PubMed ID: 33119090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan.
    Correale M; Mallardi A; Tricarico L; Mazzeo P; Ferraretti A; Diella C; Romano V; Merolla G; Iacoviello M; Di Biase M; Brunetti ND
    Acta Cardiol; 2022 Jul; 77(5):416-421. PubMed ID: 34353236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Left ventricular reverse remodeling following initiation of sacubitril/valsartan for heart failure with reduced ejection fraction and low blood pressure.
    Nishihara Y; Nishimori M; Sawa T; Uemura K; Nagai S; Todo S; Oota E; Odajima S; Takeuchi K; Ichikawa Y; Kintsu M; Yamauchi Y; Shiraki H; Yamashita K; Fukuda T; Hisamatsu E; Shimizu M; Hirata KI; Tanaka H
    Heart Vessels; 2024 Feb; 39(2):95-104. PubMed ID: 37733071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isovolumic Contraction Velocity in Heart Failure With Reduced Ejection Fraction and Effect of Sacubitril/Valsartan: the PROVE-HF Study.
    Omar AMS; Murphy S; Felker GM; Piña I; Butler J; Liu Y; Mohebi R; Bhatia K; Ward JH; Williamson KM; Solomon SD; Januzzi JL; Contreras J
    J Card Fail; 2024 May; 30(5):653-665. PubMed ID: 37816446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impacts of sacubitril/valsartan on patients eligible for cardiac resynchronization therapy.
    Huang HT; Huang JL; Lin PL; Lee YH; Hsu CY; Chung FP; Liao CT; Chiou WR; Lin WY; Liang HW; Chang HY
    ESC Heart Fail; 2022 Dec; 9(6):3825-3835. PubMed ID: 35945811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved heart function and cardiac remodelling following sacubitril/valsartan in acute coronary syndrome with HF.
    Liu H; Su Y; Shen J; Jiao Y; Li Y; Liu B; Hou X; Jin Q; Chen Y; Sun Z; Xi Q; Feng B; Fu Z
    ESC Heart Fail; 2024 Apr; 11(2):937-949. PubMed ID: 38224955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reverse Remodeling Assessed by Left Atrial and Ventricular Strain Reflects Treatment Response to Sacubitril/Valsartan.
    Moon MG; Hwang IC; Lee HJ; Kim SH; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ; Cho GY
    JACC Cardiovasc Imaging; 2022 Sep; 15(9):1525-1541. PubMed ID: 36075612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan.
    Fabiani I; Pugliese NR; Pedrizzetti G; Tonti G; Castiglione V; Chubuchny V; Taddei C; Gimelli A; Del Punta L; Balletti A; Del Franco A; Masi S; Lombardi CM; Cameli M; Emdin M; Giannoni A
    ESC Heart Fail; 2023 Oct; 10(5):2927-2938. PubMed ID: 37461184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of sacubitril/valsartan high dose tolerability in a real world population with HFrEF.
    Visco V; Radano I; Campanile A; Ravera A; Silverio A; Masarone D; Pacileo G; Correale M; Mazzeo P; Dattilo G; Giallauria F; Cuomo A; Mercurio V; Tocchetti CG; Di Pietro P; Carrizzo A; Citro R; Galasso G; Vecchione C; Ciccarelli M
    ESC Heart Fail; 2022 Oct; 9(5):2909-2917. PubMed ID: 35702942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duration of Heart Failure With Reduced Ejection Fraction Associated With Electrocardiographic Outcomes Before and After Sacubitril/Valsartan.
    Lin PL; Lee YH; Liu LY; Tsai CT; Yang TF; Chiou WR; Hsieh MY; Chang HY; Huang CC
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221107799. PubMed ID: 35713466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/valsartan effects on arrhythmias and left ventricular remodelling in heart failure: An observational study.
    Acquaro M; Scelsi L; Pasotti B; Seganti A; Spolverini M; Greco A; Schirinzi S; Turco A; Sanzo A; Savastano S; Rordorf R; Ghio S
    Vascul Pharmacol; 2023 Oct; 152():107196. PubMed ID: 37467909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reverse remodelling by sacubitril/valsartan predicts the prognosis in heart failure with reduced ejection fraction.
    Moon MG; Hwang IC; Choi W; Cho GY; Yoon YE; Park JB; Lee SP; Kim HK; Kim YJ
    ESC Heart Fail; 2021 Jun; 8(3):2058-2069. PubMed ID: 33682334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Mohanty AF; Levitan EB; King JB; Dodson JA; Vardeny O; Cook J; Herrick JS; He T; Patterson OV; Alba PR; Russo PA; Obi EN; Choi ME; Fang JC; Bress AP
    J Am Heart Assoc; 2021 Oct; 10(20):e020474. PubMed ID: 34612065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of sacubitril/valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease.
    Raphael DM; Liu Z; Jin Z; Cui X; Han D; He W; Shangguan J; Shen D
    Curr Med Res Opin; 2021 Jul; 37(7):1071-1078. PubMed ID: 33764230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.